健民集團(600976.SH):七蕊胃舒膠囊獲批上市
格隆匯1月3日丨健民集團(600976.SH)公佈,近日,公司從國家藥品監督管理局網站獲悉,公司研發的七蕊胃舒膠囊獲批上市。本品是在醫療機構製劑基礎上研製的中藥創新藥,開展了隨機、雙盲、陽性藥平行對照、多中心臨牀試驗。臨牀試驗研究結果顯示可用於輕中度慢性非萎縮性胃炎伴糜爛濕熱瘀阻證所致的胃脘疼痛的治療。該品種上市為慢性胃炎患者提供了新的治療選擇。
適應症:活血化瘀,燥濕止痛。用於輕中度慢性非萎縮性胃炎伴糜爛濕熱瘀阻證所致的胃脘疼痛,舌質紫黯或瘀斑瘀點、舌苔黃膩、脈弦澀或弦滑。
截至目前,七蕊胃舒膠囊累計投入研發費用約為人民幣2704.82萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.